PharmAla Biotech Logo 800 x 422.png
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
June 09, 2023 15:48 ET | PharmAla Biotech
Approved Study to Examine Tolerability of MDMA in Schizophrenia at UCLA VANCOUVER, British Columbia, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE:...
PharmAla Biotech Logo 800 x 422.png
PharmAla Awarded Research Grant by Ontario Centre for Innovation
June 09, 2023 13:18 ET | PharmAla Biotech
TORONTO, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)(OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA
May 16, 2023 11:37 ET | PharmAla Biotech
VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing...
Cortexa
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
May 01, 2023 18:52 ET | PharmAla Biotech
CORTEXA TO BE THE LEADING SUPPLIER OF MDMA AND PSILOCYBIN IN AUSTRALIA VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
April 25, 2023 08:00 ET | PharmAla Biotech
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (MDMA.CSE) is excited to have received a signed purchase order for GMP LaNeo MDMA and Psilocybin by Incannex...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA
April 20, 2023 08:00 ET | PharmAla Biotech
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech is proud to have been selected as the MDMA manufacturing partner for the Clinical Psychedelic Lab at Monash...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech and Filament Health Announce Release of GMP MDMA Capsules
April 11, 2023 08:00 ET | PharmAla Biotech
VANCOUVER, British Columbia, April 11, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA), a Canadian biotechnology company dedicated to the research and development of...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech named Exclusive MDMA Supply Partner to Awakn Life Sciences
March 02, 2023 08:35 ET | PharmAla Biotech
VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech Completes Annual General Meeting
March 01, 2023 08:00 ET | PharmAla Biotech
TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) has completed its first Annual General Meeting as a publicly-traded company. The company is happy to report that all motions...
PharmAla Biotech Logo 800 x 422.png
Patent Application Published for PharmAla Biotech’s MDMA Analogs
February 23, 2023 08:00 ET | PharmAla Biotech
VANCOUVER, British Columbia, Feb. 23, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce the publication of a key Patent Cooperation Treaty (PCT) application containing 6...